Aldosterone, mineralocorticoid receptor and the metabolic syndrome: Role of the mineralocorticoid receptor antagonists

Current Vascular Pharmacology

Volumn 10, Issue 2, 2012, Pages 238-246

  Ronconi, Vanessa ^a   Turchi, Federica ^a   Appolloni, Gloria ^a   di Tizio, Valentina ^a   Boscaro, Marco ^a   Giacchetti, Gilberta ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Aldosterone; Metabolic syndrome; Mineralocorticoid receptor; Mineralocorticoid receptor antagonists

Indexed keywords

ALDOSTERONE; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DROSPIRENONE; EPLERENONE; GLUCOCORTICOID RECEPTOR; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ADIPOGENESIS; ADIPOSE TISSUE; ADRENALECTOMY; ADRENERGIC SYSTEM; ALDOSTERONE BLOOD LEVEL; ARTICLE; BINDING AFFINITY; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CONFORMATION; CYSTIC FIBROSIS; DISEASE COURSE; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; ETHNICITY; GENE EXPRESSION; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HEART PROTECTION; HORMONE RECEPTOR INTERACTION; HUMAN; HYPERALDOSTERONISM; HYPERGLYCEMIA; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY DISEASE; LOW DRUG DOSE; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NONHUMAN; OBESITY; OXIDATIVE STRESS; PANCREAS ISLET CELL FUNCTION; PATHOGENESIS; PLASMA RENIN ACTIVITY; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; TISSUE DIFFERENTIATION; TREATMENT OUTCOME; WEIGHT REDUCTION;

ALDOSTERONE; ANIMALS; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; METABOLIC SYNDROME X; OXIDATIVE STRESS; RECEPTORS, MINERALOCORTICOID; VASODILATION;

EID: 84857134490     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016112799304969     Document Type: Article

References (118)

1. Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, Funder JW. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab 2008; 19: 88-90.
2. Simpson SA, Tait JF, Wettstein A, Neher R, Von Euw J, Reichstein T. Isolierung eines neuen kristallisierten Hormons aus Nebennerien mit besonders hoher Wirksamkeit auf den Mineralsoffwechsel. Experientia 1953; 9: 333-5.
3. Conn JW. Primary aldosteronism: a new clinical syndrome. J Lab Clin Med 1955; 45: 3-17.
4. Conn, JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 1964; 107: 159-72.
5. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2000; 23: S4-S19.
6. Umpierrez GE, Cantey P, Smiley D, et al. Primary aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care 2007; 30: 1699-703.
7. Corry DB, Tuck ML. The effect of aldosterone on glucose metabolism. Curr Hypertens Rep 2003; 5: 106-9.
8. Sindelka G, Widimsk J, Haas T, Prazny M, Hilgertova J, Skhra J. Insulin action in primary aldosteronism before and after surgical or pharmacological treatment. Exp Clin Endocrinol Diabetes 2000; 108: 21-5.
9. Widimsky J, Sindelka G, Haas T, Prazny M, Hilgertova J, Skhra J. Impaired insulin action in primary aldosteronism. Physiol Res 2000; 49: 241-4.
10. Skrha J, Haas T, Sindelka G, et al. Comparison of the insulin action parameters from hyperinsulinemic clamps with homeostasis model assessment and QUICKI indexes in subjects with different endocrine disorders. J Clin Endocrinol Metab 2004; 89: 135-41.
11. Widimsky J, Strauch B, Sindelka G, Skhra J. Can primary hyperaldosteronism be considered as a specific form of diabetes mellitus? Physiol Res 2001; 50: 603-7.
12. Reincke M, Meisinger C, Holle R, et al. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn's Registry. Horm Metab Res 2010; 42: 435-9.
13. Catena C, Lapenna R, Caroselli S, et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 2006; 91: 3457-63.
14. Giacchetti G, Ronconi V, Turchi F, et al. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens 2007; 25: 177-86.
15. Colussi GL, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA. Insulin resistance and hyperinsulinaemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 2007; 30: 1-6.
16. Kidambi S, Kotchen JM, Grim CE, et al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension 2007; 49: 704-11.
17. Bochud M, Nussberger J, Bovet P, et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 2006; 48: 239-45.
18. Fallo F, Veglio F, Bertello C, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 454-9.
19. Ronconi V, Turchi F, Rilli S, et al. Metabolic syndrome in primary aldosteronism and essential hypertension: relationship to adiponectin gene variants. Nutr Metab Cardiovasc Dis 2010; 20: 93-100.
20. Shimamoto K, Shiiki M, Ise T, et al. Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism. J Hum Hypertens 1994; 10: 755-9.
21. Mosso L, Carvajal CA, Maiz A, et al. A possible association between primary aldosteronism and a lower-cell function. J Hypertens 2007; 25: 2125-30.
22. Carranza MC, Torres A, Calle C. Decreased insulin receptor number and affinity in subcutaneous adipose tissue in a patient with primary hyperaldosteronism. Rev Clin Exp 1991; 188: 414-7.
23. Kraus D, Jager J, Meier B, Fasshauer M, Klein J. Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res 2005; 37: 455-9.
24. Campion J, Maestro B, Mata F, Davila N, Carranza MC, Calle C. Inhibition by aldosterone of insulin receptor mRNA levels and insulin binding in U-937 human promonocytic cells. J Steroid Biochem Mol Biol 1999; 70: 211-18.
25. Campion J, Maestro B, Molero S, Davila N, Carranza MC, Calle C. Aldosterone impairs insulin responsiveness in U-937 human promonocytic cells via the downregulation of its own receptor. Cell Biochem Funct 2002; 20: 237-45.
26. Ehrhart-Bornstein M, Arakelyan K, Krug AW, Scherbaum WA, Bornstein SR. Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. Endocr Res 2004; 30: 865-70.
27. Pierluissi J, Navas FO, Ashcroft SJ. Effect of adrenal steroids on insulin release from cultured rat islets of Langherans. Diabetologia 1986; 29: 119-21.
28. Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 2005; 16: 120-6.
29. Matrozova J, Steichen O, Amar L, Zacharieva S, Jeunemaitre X, Plouin PF. Fasting plasma glucose and serum lipids in patients with primary aldosteronism. A controlled cross-sectional study. Hypertension 2009; 53: 605-10.
30. []. Haluzik M, Sindelka G, Widimsky Jr, Prazny M, Zelinka T, Skrha J. Serum leptin levels in patients with primary hyperaldosteronism before and after treatment: relationship to insulin sensitivity. J Hum Hypertens 2002; 16: 41-5.
31. Torpy DJ, Bornstein SR, Taylor W, Tauchnitz R, Gordon RD. Leptin levels are suppressed in primary aldosteronism. Horm Metab Res 1999; 31: 533-6.
32. Fallo F, Della Mea P, Sonino N, et al. Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens 2007; 20: 855-61.
33. Iacobellis G, Petramala L, Cotesta D, et al. Adipokines and cardiometabolic profile in primary hyperaldosteronism. J Clin Endocrinol Metab 2010; 95: 2391-8.
34. Urbanet R, Pilon C, Calcagno A, et al. Analysis of insulin sensitivity in adipose tissue of patients with primary aldosteronism. J Clin Endocrinol Metab 2010; 95: 4037-42.
35. Terzolo M, Pia A, Alì A, et al. Adrenal incidentaloma: a new cause of the metabols sindrome? J Clin Endocrinol Metab 2002; 87: 998-1003.
36. Cooper SA, Whaley-Connell A, Habibi J, et al. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 2007; 293: H2009-2023.
37. Hitomi H, Kiyomoto H, Nishiyama A, et al. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 2007; 50:750-755.
38. Lastra G, Whaley-Connell A, Manrique C, et al. Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab 2008; 295: E110-6.
39. Sloniger JA, Saengsirisuwan V, Diehl CJ, et al. Defective insulin signaling in skeletal muscle of the hypertensive Tg(mREN2)27 rat. Am J Physiol Endocrinol Metab 2005; 288: E1074-81.
40. Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ. Visceral obesity and insulin resistance are associated with plasma aldoster-one levels in women. Obes Res 1999; 7: 355-362.
41. Rossi GP, Belfiore A, Bernini G, et al. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab 2008; 93: 2566-571.
42. Caprio M, Feve B, Claes A, Viengchareun S, Lombes M, Zennaro MC. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007; 21: 2185-94.
43. Caprio M, Antelmi A, Chetrite G, et al. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology 2011; 152: 113-25.
44. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-32.
45. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000; 11: 327-32
46. Sethi JK, Vidal-Puig AJ. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res 2007; 48: 1253-62.
47. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286-9.
48. Hall JE, Crook ED, Jones DW, Wofford MR, Dubbert PM. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002; 324: 127-37.
49. El-Atat F, Aneja A, Mcfarlane S, Sowers J. Obesity and hypertension. Endocrinol Metab Clin North Am 2003; 32: 823-54.
50. Fukuda N, Satoh C, Hu WY, Nakayama M, Kishioka H, Kanmatsuse K. Endogenous angiotensin II suppresses insulin signalling in vascular smooth muscle cells from spontaneously hypertensive rats. J Hypertens 2001; 19: 1651-8.
51. Zhang R, Reisin E. Obesity-hypertension: the effects on cardiovascular and renal systems. Am J Hypertens 2000; 13: 1308-14.
52. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 74-381.
53. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001; 86: 713-8.
54. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999; 353: 611-6.
55. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
56. Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879-86.
57. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: An update. Hypertension 2001; 37: 1053-9.
58. Bloem LJ, Manatunga AK, Tewsbury DA, Pratt JH. The serum angiotensinogen concentration and variants of the angiotensinogen. gene in white and black children. J Clin Invest 1995; 95: 948-53.
59. Cooper R, McFarlane-Anderson N, Bennett FI, et al. ACE, angiotensinogen and obesity: a potential pathway leading to hypertension. J Hum Hypertens 1997; 11: 107-11.
60. Messerli FH, Christie B, DeCarvalho JG, et al. Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. Arch Intern Med 1981; 141: 81-5.
61. Massiera F, Bloch-Faure M, Ceiler D, et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEBJ 2001; 15: 2727-9.
62. Faloia, E, Gatti C, Camilloni MA, et al. Comparison of circulating and local adipose tissue renin-angiotensin system in normotensive and hypertensive obese subjects. J Endocrinol Invest 2002; 25: 309-14.
63. Giacchetti G, Faloia E, Mariniello B, et al. Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertens 2002; 15: 381-8.
64. Licata, G, Scaglione R, Ganguzza A, et al. Central obesity and hypertension: relationship between fasting serum insulin, plasma renin activity, and diastolic blood pressure in young obese subjects. Am J Hypertens 1994; 7: 314-20.
65. Egan BM, Stepniakowski K, Goodfriend TL. Renin and aldosterone are higher and the hyperinsulinemic effect of salt restriction greater in subjects with risk factors clustering. Am J Hypertens 1994; 7: 886-93.
66. El Gharbawy AH, Nadig VS, Kotchen JM, et al. Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension 2001; 37: 845-50.
67. Engeli S, Bohne J, Gorzelniak K, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005; 45: 356-62.
68. Harp JB, Henry SA, Di Girolamo M. Dietary weight loss decreases serum angiotensin-converting enzyme activity in obese adults. Obes Res 2002; 10: 985-90.
69. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981; 304: 930-3.
70. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven V, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci USA 2003; 100: 14211-6.
71. Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 2004; 43: 358-63.
72. Krug AW, Vleugels K, Schinner S, et al. Human adipocytes induce an ERK1/2 MAP kinases-mediated upregulation of steroidogenic acute regulatory protein (StAR) and an angiotensin II-sensitization in human adrenocortical cells. Int J Obes 2007; 31: 1605-16.
73. Nagase M, Yoshida S, Shibata S, et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 2006; 17: 3438-46.
74. Funder JW, Feldman D, Edelman IS. The roles of plasma binding and receptor specificity in the Mineralocorticoid action of aldosterone. Endocrinology 1973; 92: 994-1004.
75. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor mediated. Science 1988; 242: 583-5.
76. Lombes M, Kenouch S, Souque A, Farman N, Rafestin-Oblin ME. The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11 beta-hydroxysteroid dehydrogenase. Endocrinology 1994; 135: 834-40.
77. Stewart PM, Corrie JE, Shackleton CH, Edwards CR. Syndrome of apparent mineralocorticoid excess: a defect in the cortisol-cortisone shuttle. J Clin Invest 1988; 82: 340-9.
78. Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR. Mineralocorticoid activity in licorice: 11 betahydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987; 2: 821.
79. de Kloet ER, van Acker SA, Sibug R, et al. Brain mineralocorticoid receptors and centrally regulated functions. Kidney Int 2000; 57: 1329-36.
80. DeRijk RH, Wust S, Meijer OC, et al. A common polymorphism in the mineralocorticoid receptor modulates stress responsiveness. J Clin Endocrinol Metab 2006; 91: 5083-9.
81. Wehling M, Eisen C, Christ M. Aldosterone-specific membrane receptors and rapid non-genomic actions of mineralocorticoids. Mol Cell Endocrinol 1992; 90: C5-9.
82. Passaquin AC, Lhote P, Ruegg UT. Calcium influx inhibition by steroids and analogs in C2C12 skeletal muscle cells. Br J Pharmacol 1998; 124: 1751-9.
83. Doolan CM, Condliffe SB, Harvey BJ. Rapid non-genomic activation of cytosolic cyclic AMP-dependent protein kinase activity and [Ca(2+)] (i) by 17--estradiol in female rat distal colon. Br J Pharmacol 2000; 129: 1375-86.
84. Chun TY, Pratt JH. Non-genomic effects of aldosterone: new actions and questions. Trends Endocrinol Metab 2004; 15: 353-4.
85. Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M. Multiple actions of steroid hormones-a focus on rapid, nongenomic effects. Pharmacol Rev 2000; 52: 513-56.
86. 2+ levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology 2005; 146: 973-80.
87. Funder JW. The non-genomic actions of aldosterone. Endocr Rev 2005; 26: 313-21.
88. Selye H. The general adaptation syndrome and the diseases of adaptation. J Clin Endocrinol Metab 1946; 6: 117-230.
89. Arriza JL,Weinberger C. Cerelli G. et al. Cloning of human miner-alocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987; 237: 268-75.
90. Fuller PJ, Lim-Tio SS, Brennan FE. Specificity in mineralocorticoid vs. glucocorticoid action. Kidney Int 2000; 57: 1256-64.
91. Viengchareun S, Penfornis P, Zennaro MC, Lombes M. Mineralocorticoid and glucocorticoid receptors inhibit UCP expression and function in brown adipocytes. Am J Physiol Endocrinol Metab 2001; 280: E640-9.
92. Casal AJ, Silvestre JS, Delcayre C, Capponi AM. Expression and modulation of sterodiogenic acute regulatory protein messenger ribonucleic acid in rat cardiocytes and after myocardial infarction. Endocrinology 2003; 144: 1861-8.
93. Yamashita R, Kikuchi T, Mori Y, et al. Aldosterone stimulates gene expression of hepatic gluconeogenic enzymes through the glucocorticoid receptor in a manner independent of the protein kinase B cascade. Endocr J 2004; 51: 243-51.
94. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomize Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
95. Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone a selective, aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New Engl J Med 2003; 348: 1309-21.
96. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens 2007; 25: 1751-62.
97. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 2006; 119: 912-9.
98. Hauner H, Entenmann G, Wabitscj M, et al. Promoting effects of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. J Clin Invest 1989; 84:1663-70.
99. Rondinone CM, Rodbard D, Baker ME. Aldosterone stimulates differentiation of mouse 3T3-L1 cells into adipocytes. Endocrinology 1993; 132: 2421-6.
100. Zennaro MC, Le Menuet D, Viengchareun S, Walker F, Ricquier D, Lombès M. Hibernoma development in transgenic mice identifies brown adipose tissue as a novel target of aldosterone action. J Clin Invest 1998; 101: 1254-60.
101. Fu M, Sun T, Bookout AL, Yu RT, Evans RM, Mangelsdorf DJ. A nuclear receptor atlas: 3T3-L1 adipogenesis. Mol Endocrinol 2005; 19: 2437-50.
102. Guo C, Ricchiuti V, Lian BQ, et al. Mineralocortciocid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-, and proinflammatory adipokines. Circulation 2008; 117: 2253-61.
103. Hirata A, Maeda N, Hiuge A, et al. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 2009; 84: 164-72.
104. Tokita Y, Yamaguchi T, Franco-Saenz R, Mulrow PJ, Ganten D. Adrenal renin is released into the circulation of the hypertensive transgenic rat TGR (mRen-2)27. Trans Assoc Am Physicians 1992; 105: 123-32.
105. Wellen KE, Hotamisligil GS. Obesity-induced inflammation changes in adipose tissue. J Clin Invest 2003; 112: 1785-8.
106. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-30.
107. Wada T, Kenmochi H, Miyashita Y, et al. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology 2010; 151: 2040-9.
108. Waanders F, de Vries LV, van Goor H, et al. Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage. Curr Vasc Pharmacol 2011; 9: 594-605.
109. Jandeleit-Dahm KAM, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23: 463-73.
110. Kang YS, Lee MH, Song HK, et al. Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice. Nephrol Dial Transplant 2011; 26: 1194-204.
111. Iwai M, Kanno H, Tomono Y, et al. Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-A(y) mice. J Hypertens 2010; 28: 1471-81.
112. Fogari R, Zoppi A, Mugellini A, Lazzari P, Derosa G. Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome. Horm Metab Res 2010; 42: 892-6.
113. Cagnoni F, Njwe CA, Zaninelli A, et al. Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination. Vasc Health Risk Manag 2010; 6: 549-59.
114. Lastra G, Habibi J, Whaley-Connell AT, et al. Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology 2009; 150: 2561-8.
115. Mulatero P, Rabbia F, Milan A, et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40: 897-902.
116. Deedwania P. Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating-blockers. J Clin Hypertens 2011; 13: 52-9.
117. Dell'Omo G, Penno G, Del Prato S, Pedrinelli R. Doxazosin in metabolically complicated hypertension. Expert Rev Cardiovasc Ther 2007; 5: 1027-35.
118. Dronavalli S, Bakris GL. Mechanistic insights into diuretic-induced insulin resistance. Hypertension 2008; 52: 1009-11.